Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
On Monday, BMO Capital Markets initiated coverage on Vital Farms (NASDAQ:VITL), assigning the stock an Outperform rating with a price target of $44.00. This target suggests a potential upside of approximately 23% from the stock’s current trading level of $35.54. According to InvestingPro data, analyst targets range from $39 to $52, with the company receiving a "GREAT" financial health score.
Vital Farms, recognized for its high-growth trajectory, primarily operates in the production, marketing, and distribution of pasture-raised eggs and butter. The company has demonstrated impressive performance with revenue growth of 28.49% over the last twelve months. BMO Capital’s optimism is rooted in the company’s strong brand and growth prospects, despite a forecast of slower growth in the first quarter of 2025 due to anticipated lower volumes.
The firm’s analysts project that Vital Farms will surpass its 2025 financial guidance, which anticipates over $750 million in sales and more than $100 million in adjusted EBITDA. The confidence stems from an expected increase in volumes during the second half of the year. InvestingPro analysis reveals the company maintains strong fundamentals with a current ratio of 3.13 and minimal debt, suggesting solid financial positioning for future growth. Get access to 10+ additional ProTips and comprehensive financial metrics with InvestingPro.
BMO Capital has based its $44 price target for Vital Farms on a 2x enterprise value to sales (EV/Sales) multiple applied to their 2026 sales estimate. The projection indicates the firm’s belief in the company’s value and its future performance in the market.
Vital Farms’ focus on branded food products and its positioning within the market contribute to the positive outlook provided by BMO Capital, signaling potential growth and profitability in the coming years.
In other recent news, Vital Farms has been the subject of several analyst reviews and updates. Telsey Advisory Group reaffirmed its Outperform rating with a $52 price target, citing robust revenue expansion driven by increased demand for pasture-raised eggs and strategic distribution efforts. Meanwhile, Morgan Stanley (NYSE:MS) initiated coverage with an Overweight rating and a $40 price target, emphasizing a positive growth outlook based on consumer preferences and distribution plans. Stifel maintained its Buy rating and a $44 price target, projecting a 23% revenue increase for 2025 and highlighting potential upside as growth accelerates.
DA Davidson also maintained a Buy rating but adjusted its price target slightly to $42 from $43, following a field trip to Vital Farms’ facilities. The firm noted the company’s strong relationships with family farms and recent technological advancements, such as a new automated egg grading system. Additionally, DA Davidson reaffirmed a Buy rating with a $44 price target, praising Vital Farms’ fourth-quarter performance and optimistic fiscal year 2025 guidance. The guidance suggests revenue growth above standard rates and margins at the higher end of long-term targets, reflecting confidence from the company’s management. These recent developments indicate a strong focus on growth and operational efficiency for Vital Farms.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.